NCT04345471View on ClinicalTrials.gov

A Study of MD-120 in Patients With Depression

PHASE3CompletedINTERVENTIONAL
Enrollment

615

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

July 21, 2022

Study Completion Date

September 14, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

Desvenlafaxine 100 mg

once daily dosing for 8 weeks

DRUG

Desvenlafaxine 50 mg

once daily dosing for 8 weeks

DRUG

Placebo

once daily dosing for 8 weeks

Trial Locations (1)

Unknown

Mochida Investigational sites, Tokyo

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Mochida Pharmaceutical Company, Ltd.

INDUSTRY